We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ZYNLONTA Swedish Orphan Biovitrum Pty Ltd
Product name
ZYNLONTA
Sponsor
Accepted date
Mar-2025
Active ingredients
loncastuximab tesirine
Proposed indication
Zynlonta (loncastuximab tesirine) is used to treat adult patients with diffuse large B cell lymphoma that has come back or did not respond to at least two other treatments. Lymphoma develops when white blood cells (lymphocytes) grow out of control.
Application type
A (new medicine)
Publication date
Mar-2025
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.